Experimental Drug Daraxonrasib Shows First Major Survival Benefit for Pancreatic Cancer Patients
By
Gina Kolata, Rebecca Robbins
Crusty in the right places. Worth the chew.
Summary
An experimental drug called daraxonrasib has become the first treatment to substantially extend the lives of pancreatic cancer patients in a clinical trial. Pancreatic cancer has long been one of the most difficult cancers to treat, with few effective options and decades of failed experimental drugs. The breakthrough challenges long-held beliefs about the biological obstacles being insurmountable, and the new strategy also shows promise for lung and colon tumors.
Key quotes
· 5 pulledPancreatic cancer is one of the most dire diagnoses in medicine.
There are few available treatments, and they do little to help.
For decades, experimental drugs flopped in trials.
Many researchers believed the biological obstacles could not be surmounted.
In what seems the blink of an eye, all that has changed.
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·13d ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo ago
Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch
The article discusses a promising new drug that targets pancreatic tumors and may have revealed a "master switch" for cancer. The treatment
economist.com·5h ago
Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic
rockefeller.edu·9mo ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
TAR-200 Drug System Eliminates Bladder Cancer in 82% of Resistant Patients
A new drug-releasing system, TAR-200, has shown remarkable success in treating high-risk non-muscle-invasive bladder cancer, eliminating tum
news.keckmedicine.org·10mo ago